Serum Selenium Levels Predict Breast Cancer Prognosis

Research done in southern Sweden shows that three blood biomarkers of selenium availability correlated inversely with mortality from breast cancer. The lower the three selenium biomarker levels, the higher the mortality [Demircan 2021].

Breast cancer pink ribbon
Assessment of selenium status at the time of breast cancer diagnosis identifies patients at exceptionally high risk for a poor prognosis. They are breast cancer patients with low levels of selenium, selenoprotein P, and glutathione peroxidase in their blood.

The blood biomarkers are:

  • Total selenium
  • Selenoprotein P
  • Glutathione peroxidase 3

Breast cancer patients with blood concentrations of these three selenium biomarkers in the highest quintile had significantly better chances of survival compared with patients whose blood levels of these substances were in the lowest quintile [Demircan 2021].

Breast cancer patients with low selenium status according to these three biomarkers had the highest mortality risk with an overall survival probability of approximately 50% after 8 years. The difference in survival between the breast cancer patients in the lowest selenium quintile compared to breast cancer patients with at least one biomarker in the highest quintile was especially notable [Demircan 2021]. read more

Selenium Supplementation for Senior Citizens

Health benefits of daily supplementation of senior citizens with a combination of selenium and Coenzyme Q10:

  • improved heart function as shown on echocardiograms
  • reduced risk of death from heart disease
  • improved health-related quality of life
Professor Urban Alehagen
In the KiSel-10 Study, Prof. Urban Alehagen and the research team administered 200 mcg/day of selenium and 2 x 100 mg/day of Coenzyme Q10 for 48 months to elderly Swedish citizens whose serum selenium status at baseline was quite low (mean: 67.1 mcg/L). The duration of the study was 48 months. The benefits of the supplementation were improved heart function and reduced risk of death from heart disease.

The combined supplementation seems to work by reducing the extent of oxidative stress, systemic inflammation, and fibrosis in the study participants [Alehagen 2022a].

Now, data from the KiSel-10 Study show the following effects of the combined supplementation with respect to Fibroblast Growth Factor 23 concentrations in blood:

  • Supplementation decreased concentrations of FGF-23 hormones.
  • The study showed a relationship between the circulating level of the FGF-23 and atrial fibrillation.
  • The study showed an association between the concentration of FGF-23 and death from heart disease.
  • The study showed an effect of reduced FGF-23 levels on the risk of death from heart disease that is independent of the level of the cardiac wall tension bio-marker NT-proBNP.
  • There exists a close interrelationship between FGF-23 concentrations and kidney function.
Why are FGF-23 Concentrations Important?

Prof. Alehagen explains that FGF-23 is a hormone that is secreted into the blood circulation. One of its primary functions is the regulation of the vitamin D metabolism and of the phosphorous metabolism in the kidneys.

However, there seems to be an association between FGF-23 activity and cardiovascular mortality even in the absence of kidney disease. Experimental data show that FGF-23 may act as a mediator for cardiac hypertrophy, cardiac fibrosis, and cardiac dysfunction [Alehagen 2022b]. read more